Compare DOGZ & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 116.8M |
| IPO Year | 2017 | 2020 |
| Metric | DOGZ | BDTX |
|---|---|---|
| Price | $1.53 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 150.8K | ★ 584.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $1.20 |
| 52 Week High | $34.53 | $4.94 |
| Indicator | DOGZ | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.30 | 46.98 |
| Support Level | $1.36 | $2.19 |
| Resistance Level | $1.71 | $2.67 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 39.74 | 47.01 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.